<DOC>
	<DOCNO>NCT00636636</DOCNO>
	<brief_summary>Gabapentin pregabalin treatment type neuropathic pain , include postherpetic neuralgia ( PHN ) . However , treatment usually need take 3 time day effective pain control . The purpose study determine whether new gabapentin tablet , need take day , safe effective treatment postherpetic neuralgia .</brief_summary>
	<brief_title>Safety Efficacy Gabapentin Postherpetic Neuralgia</brief_title>
	<detailed_description>The primary study objective ass relative efficacy G-ER dose daily ( 1800 mg follow even meal ) , versus placebo reduce mean daily pain score baseline week end efficacy treatment period ( Treatment Week 10 ) patient PHN . Secondary efficacy measure include change baseline mean weekly sleep interference score , Short-Form McGill Pain Questionnaire ( SF-MPQ ) , Neuropathic Pain Scale ( NPS ) , Brief Pain Inventory ( BPI ) , Patient Global Impression Change ( PGIC ) , Investigator-Rated Clinical Global Impression Change ( CGIC ) .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Men woman 18 year old experience pain least 6 month , 5 year heal herpes zoster skin rash ( typically 4 month rash first appear ) . 2 . Patient pain intensity score least 4 11point Numerical Rating Scale ( NRS ) . Patients never inform pain intensity criterion prior screen randomization . 3 . Patients childbearing potential must negative serum pregnancy test screen negative followup urine pregnancy test randomization . 4 . Patient mean baseline week pain intensity score least 4 11point NRS scale end 1week baseline period complete least 4 day daily pain diary entry baseline week . 5 . Patients must minimum washout period great 5 time halflife drug several medication . 6 . Patients currently treat gabapentin pr pregabalin screen may eligible study , must taper period wherein dose gabapentin pregabalin reduce gradually period 5 day follow two day washout prior Baseline Week . 1 . Patients previously respond treatment PHN gabapentin pregabalin . 2 . Patients previously experience doselimiting adverse effect prevent titration gabapentin effective dose . 3 . Patient nursing mother . 4 . Patient hypersensitivity gabapentin . 5 . Patient neurolytic neurosurgical treatment PHN . 6 . Patient severe pain cause PHN . 7 . Patient use injected anesthetic steroid within 30 day baseline . 8 . Patient skin condition area affect neuropathy could alter sensation . 9 . Patient immunocompromised state . 10 . Patient estimate creatinine clearance le 50 ml/min . 11 . Patient malignancy within past 2 year basal cell carcinoma . 12 . Patient gastric reduction surgery . 13 . Patient severe chronic diarrhea , chronic constipation [ unless attribute drug wash ] , uncontrolled irritable bowel syndrome ( IBS ) unexplained weight loss . 14 . Patient abnormal chemistry hematology result deem investigator clinically significant . 15 . Patient history substance abuse within past year . 16 . Patient history seizure ( except infantile febrile seizure ) risk seizure due head trauma . 17 . Patient history chronic hepatitis B C , hepatitis within past 3 month , HIV infection . 18 . Patient clinically significant medical psychological condition , opinion Investigator would jeopardize safety patient affect validity study result . 19 . Continuing use concomitant medication exclude Inclusion Criterion 5 . 20 . Patient participate clinical trial investigational drug device within 30 day screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Postherpetic Neuralgia ( PHN ) , shingle</keyword>
</DOC>